Search in:

Therapeutics and Clinical Risk Management Volume 14, 2018 - Issue

Submit an article Journal homepage

Open access

102

Views

CrossRef citations to date

Altmetric

Review

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes

Giuseppe Derosa1 Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [email protected];2 Centre for Prevention, Surveillance, Diagnosis and Treatment of Rare Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, [email protected];3 Laboratory of Molecular Medicine, University of Pavia, Pavia, Italy, [email protected]Correspondence[email protected]

Pamela Maffioli1 Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [email protected]

Pages 1637-1640 | Published online: 07 Sep 2018

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (9)

Bo Pang, Lu-Lu Zhang, Bin Li, Feng-Xian Sun & Zhi-Da Wang. (2023) The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation. Physiology & Behavior 263, pages 114134.
Crossref

Rosanna Maccari & Rosaria Ottanà. (2022) Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives. Journal of Medicinal Chemistry 65:16, pages 10848-10881.
Crossref

Li Liu, Fang-Hong Shi, Hua Xu, Yue Wu, Zhi-Chun Gu & Hou-Wen Lin. (2022) Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 12.
Crossref

Juan F. Rivelli Antonelli, Verónica S. Santander, Ayelen D. Nigra, Noelia E. Monesterolo, Gabriela Previtali, Emilianao Primo, Lisandro H. Otero & César H. Casale. (2021) Prevention of tubulin/aldose reductase association delays the development of pathological complications in diabetic rats. Journal of Physiology and Biochemistry 77:4, pages 565-576.
Crossref

Shih-Wei Lai, Kuan-Fu Liao, Yu-Hung Kuo, Cheng-Li Lin, Chiu-Shong Liu & Bing-Fang Hwang. (2021) A Head-To-Head Comparison of Benzbromarone and Allopurinol on the Risk of Type 2 Diabetes Mellitus in People With Asymptomatic Hyperuricemia. Frontiers in Pharmacology 12.
Crossref

Ning Li, Ruimin Chen & Kewei Liu. (2020) Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus. Clinical Drug Investigation 40:11, pages 991-1000.
Crossref

Tina Schumann, Jörg König, Christine Henke, Diana M. Willmes, Stefan R. Bornstein, Jens Jordan, Martin F. Fromm & Andreas L. Birkenfeld. (2019) Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease. Pharmacological Reviews 72:1, pages 343-379.
Crossref

Andreea-Daniela Meca, Liliana Mititelu Tarțău, Eliza Grațiela Popa, Carmen Gafițanu, Andreea Crețeanu & Maria Bogdan. (2019) New perspectives on oral antidiabetics therapy. Farmacist.ro 187 (2):1, pages 25-28.
Crossref

Murat Calapkulu, Soner Cander, Ozen Oz Gul & Canan Ersoy. (2019) Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13:2, pages 1031-1034.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes

Articles from other publishers (9)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes

Citations (9)

Articles from other publishers (9)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date